The KDM4C-specific epigenetic inhibitor SD70 can reshape the tumor state, activate the expression of CXCL10, and enhance the recruitment and activation of CD8+ T cells, ultimately making tumors more responsive to RT and immunotherapy (figure 7). This evidence concerns the gene CXCL10 and neoplasm.